Cardiol’s CRD-38 holds potential to differentiate in HF space: GlobalData
CRD-38’s alternative mechanism positions it as a potential new option in heart failure treatment
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Sionna Therapeutics’ NBD1 stabilisers hold potential to differentiate from Vertex’s existing…
Sionna’s IPO signals investor interest amid competitive cystic fibrosis treatment landscape
Zydus launches India’s first flu vaccine for southern hemisphere 2025 strain
VaxiFlu-4 developed as per WHO-recommended composition for influenza protection
Lupin included in S&P Global Sustainability Yearbook 2025 for the second consecutive year
Lupin’s S&P Global CSA score has significantly improved from 65 to 75 in 2024
Glenmark announces launch of Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) multiple-dose vial
The launch is eligible for 180 days of CGT exclusivity under the FD&C Act
Motilal Oswal Alternates invests up to INR 460 crores for majority stake in Megafine
The Sanghvi family increases its stake in Megafine as part of the transaction
USFDA classifies inspection at Dr Reddy’s API facility as Voluntary Action Indicated
Dr Reddy’s Laboratories receives Establishment Inspection Report for its API manufacturing facility in Bollaram, Hyderabad
Nutraceuticals in preventive healthcare: Regulatory advancements and market growth highlighted at…
Experts at the 10th Nutraceutical Summit emphasise regulatory frameworks, market expansion, and the integration of Ayurveda in…
EY-Parthenon and Microsoft launch AI framework to guide life sciences sector transformation
Report unveiled at BioAsia 2025 outlines AI adoption strategies for scaling innovation in pharmaceuticals, medtech, and academic…
India’s CRDMO sector growth potential at $22 – $25 billion by 2035: Report
Report states that India’s CRDMO sector is poised for rapid growth with strong fundamentals and global realignments, focusing on…